• Pulmotect Receives First Tranche of $8.9 Million from The State of Texas
• Pulmotect Awarded $8.9 Million from The State of Texas
• Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19
• Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19
• Pulmotect Appoints William J. Noss III as Chief Financial Officer
• Pulmotect Awarded Up To $6M From Department of Defense to Complete Two COVID-19 Trials
• Coronavirus protection drug approved by FDA for testing in Houston
  KTRK ABC 13 - July 10, 2020
• Houston biotech company gets green light from FDA to test coronavirus-fighting drug
  InnovationMap - May 2020
• Houston company testing drug to protect against COVID 19
  KTRK-TV Houston - ABC 13 - May 2020
• Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19
• Houston company working on possible COVID-19 treatment
  Houston Fox 26 News - March 2020
• Houston biotech co.’s coronavirus treatment candidate to undergo clinical trials
  Houston Business Journal - March 2020
• Houston researchers test lung inhalant that could protect healthcare workers from COVID-19
  Houston Chronicle - March 2020
• Pulmotect’s PUL-042 Shows Promising Pre-Clinical Efficacy in Preventing Lethal Coronavirus Infection
• Pulmotect Announces Initial Close on $12 Million Series B
• Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug
  Scrip - June 2017
• Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
  BioSpace - June 2017
• Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
• Pulmotect Convenes Inaugural Scientific Advisory Board
  BioSpace - June 2017
• Pulmotect Convenes Inaugural Scientific Advisory Board